🇺🇸 Liposomal Amphotericin B in United States

171 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 49 reports (28.65%)
  2. Respiratory Failure — 19 reports (11.11%)
  3. Acute Kidney Injury — 16 reports (9.36%)
  4. Drug Interaction — 16 reports (9.36%)
  5. Pneumonia — 14 reports (8.19%)
  6. Aspergillus Infection — 13 reports (7.6%)
  7. Multiple Organ Dysfunction Syndrome — 13 reports (7.6%)
  8. Bronchopulmonary Aspergillosis — 11 reports (6.43%)
  9. Condition Aggravated — 10 reports (5.85%)
  10. Drug Level Increased — 10 reports (5.85%)

Source database →

Other Infectious Disease approved in United States

Frequently asked questions

Is Liposomal Amphotericin B approved in United States?

Liposomal Amphotericin B does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Liposomal Amphotericin B in United States?

Taiwan Liposome Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.